Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma
暂无分享,去创建一个
C. Morosi | R. Luksch | C. Meazza | M. Podda | M. Casanova | S. Catania | V. Biassoni | A. Ferrari | E. Zaffignani | F. Favini
[1] D. Rodeberg,et al. Randomized phase III trial comparing vincristine, actinomycin, cyclophosphamide (VAC) with VAC/V topotecan/cyclophosphamide (TC) for intermediate risk rhabdomyosarcoma (IRRMS). D9803, COG study , 2007 .
[2] James R. Anderson,et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] W. Meyer,et al. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Pollock,et al. Soft Tissue Sarcomas , 2001, CA: a cancer journal for clinicians.
[5] P. Houghton,et al. Topoisomerase I interactive drugs in children with cancer , 2004, Investigational New Drugs.
[6] P. Houghton,et al. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors , 2004, Cancer Chemotherapy and Pharmacology.
[7] G. Severi,et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma , 2003, Cancer.
[8] M. Bernstein,et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Meza,et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] James R. Anderson,et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Houghton,et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] P. Houghton,et al. Animal models for studying the action of topoisomerase I targeted drugs. , 1998, Biochimica et biophysica acta.
[13] M. Bernstein,et al. Topotecan in Pediatric Patients With Recurrent and Progressive Solid Tumors: A Pediatric Oncology Group Phase II Study , 1998, Journal of pediatric hematology/oncology.
[14] R. Larsson,et al. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients , 1998, European Journal of Clinical Pharmacology.
[15] J. Verweij,et al. Review of phase I clinical studies with topotecan. , 1997, Seminars in oncology.
[16] S. Kaufmann,et al. Topotecan in combination chemotherapy. , 1997, Seminars in oncology.
[17] J. Ross,et al. Epidemiology of acute leukemia in children and adults. , 1997, Seminars in oncology.
[18] J. Kurtzberg,et al. Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five‐Day Course in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study , 1996, Journal of pediatric hematology/oncology.
[19] E. Gehan,et al. The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Chatterjee,et al. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. , 1994, Oncology research.
[21] R. Kim,et al. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice , 1992, International journal of cancer.
[22] S. George,et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] B Sundell,et al. Soft-tissue sarcomas. , 1979, British medical journal.